Tempus AI vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI precision medicine company. NASDAQ: TEM. 2025 revenue $1.27B (+83% YoY). World's largest clinical/molecular data library. Founded 2015, Chicago. 2026 guidance ~$1.59B.
About
Tempus AI is an AI-powered precision medicine company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has built the world's largest library of clinical and molecular data, comprising over 40 million research records including 1.5 million with matched clinical-genomic data. Tempus provides precision medicine services across oncology, cardiology, radiology, and depression through Genomics, Data and Services, and AI Applications product lines.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.